265 related articles for article (PubMed ID: 23155437)
1. Inflamm-aging and arachadonic acid metabolite differences with stage of tendon disease.
Dakin SG; Dudhia J; Werling NJ; Werling D; Abayasekara DR; Smith RK
PLoS One; 2012; 7(11):e48978. PubMed ID: 23155437
[TBL] [Abstract][Full Text] [Related]
2. Macrophage sub-populations and the lipoxin A4 receptor implicate active inflammation during equine tendon repair.
Dakin SG; Werling D; Hibbert A; Abayasekara DR; Young NJ; Smith RK; Dudhia J
PLoS One; 2012; 7(2):e32333. PubMed ID: 22384219
[TBL] [Abstract][Full Text] [Related]
3. Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure.
Tourki B; Kain V; Pullen AB; Norris PC; Patel N; Arora P; Leroy X; Serhan CN; Halade GV
Mol Metab; 2020 Jan; 31():138-149. PubMed ID: 31918915
[TBL] [Abstract][Full Text] [Related]
4. Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄.
Hanson J; Ferreirós N; Pirotte B; Geisslinger G; Offermanns S
Biochem Pharmacol; 2013 Jun; 85(12):1795-802. PubMed ID: 23643932
[TBL] [Abstract][Full Text] [Related]
5. Inflammation activation and resolution in human tendon disease.
Dakin SG; Martinez FO; Yapp C; Wells G; Oppermann U; Dean BJ; Smith RD; Wheway K; Watkins B; Roche L; Carr AJ
Sci Transl Med; 2015 Oct; 7(311):311ra173. PubMed ID: 26511510
[TBL] [Abstract][Full Text] [Related]
6. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.
Maderna P; Cottell DC; Toivonen T; Dufton N; Dalli J; Perretti M; Godson C
FASEB J; 2010 Nov; 24(11):4240-9. PubMed ID: 20570963
[TBL] [Abstract][Full Text] [Related]
7. Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature.
Brancaleone V; Dalli J; Bena S; Flower RJ; Cirino G; Perretti M
J Immunol; 2011 Apr; 186(8):4905-14. PubMed ID: 21398608
[TBL] [Abstract][Full Text] [Related]
8. Lack of activity of 15-epi-lipoxin A₄ on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function.
Planagumà A; Domenech T; Jover I; Ramos I; Sentellas S; Malhotra R; Miralpeix M
Clin Exp Immunol; 2013 Aug; 173(2):298-309. PubMed ID: 23607720
[TBL] [Abstract][Full Text] [Related]
9. Treating neutrophilic inflammation in COPD by targeting ALX/FPR2 resolution pathways.
Bozinovski S; Anthony D; Anderson GP; Irving LB; Levy BD; Vlahos R
Pharmacol Ther; 2013 Dec; 140(3):280-9. PubMed ID: 23880288
[TBL] [Abstract][Full Text] [Related]
10. Lipoxin A
Gaudin A; Tolar M; Peters OA
Sci Rep; 2018 Jun; 8(1):8921. PubMed ID: 29892010
[TBL] [Abstract][Full Text] [Related]
11. Lipoxin-mediated signaling: ALX/FPR2 interaction and beyond.
Sánchez-García S; Jaén RI; Fernández-Velasco M; Delgado C; Boscá L; Prieto P
Pharmacol Res; 2023 Nov; 197():106982. PubMed ID: 37925045
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of the formyl peptide receptor 2 gene.
Simiele F; Recchiuti A; Patruno S; Plebani R; Pierdomenico AM; Codagnone M; Romano M
Biochim Biophys Acta; 2016 Oct; 1859(10):1252-8. PubMed ID: 27424221
[TBL] [Abstract][Full Text] [Related]
13. Divergent roles of prostacyclin and PGE
Bergqvist F; Carr AJ; Wheway K; Watkins B; Oppermann U; Jakobsson PJ; Dakin SG
Arthritis Res Ther; 2019 Mar; 21(1):74. PubMed ID: 30867043
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-181b regulates ALX/FPR2 receptor expression and proresolution signaling in human macrophages.
Pierdomenico AM; Recchiuti A; Simiele F; Codagnone M; Mari VC; Davì G; Romano M
J Biol Chem; 2015 Feb; 290(6):3592-600. PubMed ID: 25505240
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and cancer: role of annexin A1 and FPR2/ALX in proliferation and metastasis in human laryngeal squamous cell carcinoma.
Gastardelo TS; Cunha BR; Raposo LS; Maniglia JV; Cury PM; Lisoni FC; Tajara EH; Oliani SM
PLoS One; 2014; 9(12):e111317. PubMed ID: 25490767
[TBL] [Abstract][Full Text] [Related]
16. Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury.
Bonnans C; Fukunaga K; Levy MA; Levy BD
Am J Pathol; 2006 Apr; 168(4):1064-72. PubMed ID: 16565483
[TBL] [Abstract][Full Text] [Related]
17. Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endothelium.
Chinthamani S; Odusanwo O; Mondal N; Nelson J; Neelamegham S; Baker OJ
Am J Physiol Cell Physiol; 2012 Apr; 302(7):C968-78. PubMed ID: 22205391
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis.
Vong L; Ferraz JG; Dufton N; Panaccione R; Beck PL; Sherman PM; Perretti M; Wallace JL
PLoS One; 2012; 7(6):e39244. PubMed ID: 22723974
[TBL] [Abstract][Full Text] [Related]
19. The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability.
Petri MH; Laguna-Fernández A; Gonzalez-Diez M; Paulsson-Berne G; Hansson GK; Bäck M
Cardiovasc Res; 2015 Jan; 105(1):65-74. PubMed ID: 25341894
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis of tendon extracellular matrix reveals disease stage-specific fragmentation and differential cleavage of COMP (cartilage oligomeric matrix protein).
Dakin SG; Smith RK; Heinegård D; Önnerfjord P; Khabut A; Dudhia J
J Biol Chem; 2014 Feb; 289(8):4919-27. PubMed ID: 24398684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
